Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report)'s share price gapped up before the market opened on Wednesday . The stock had previously closed at $14.48, but opened at $15.00. Sionna Therapeutics shares last traded at $14.88, with a volume of 6,051 shares changing hands.
Analysts Set New Price Targets
SION has been the topic of a number of recent research reports. TD Cowen assumed coverage on shares of Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a "buy" rating on the stock. Guggenheim assumed coverage on shares of Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a "buy" rating and a $45.00 price target on the stock. Wall Street Zen cut shares of Sionna Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Finally, Stifel Nicolaus assumed coverage on shares of Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a "buy" rating and a $32.00 price objective on the stock.
Check Out Our Latest Stock Report on SION
Sionna Therapeutics Stock Performance
The company has a 50 day moving average of $11.92.
Sionna Therapeutics (NASDAQ:SION - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.17).
Institutional Investors Weigh In On Sionna Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in SION. Jennison Associates LLC bought a new stake in Sionna Therapeutics during the 1st quarter worth approximately $8,995,000. TD Asset Management Inc bought a new stake in Sionna Therapeutics during the 1st quarter worth approximately $579,000. Charles Schwab Investment Management Inc. bought a new stake in Sionna Therapeutics during the 1st quarter worth approximately $676,000. CenterBook Partners LP bought a new stake in Sionna Therapeutics during the 1st quarter worth approximately $1,195,000. Finally, Aberdeen Group plc bought a new stake in Sionna Therapeutics during the 1st quarter worth approximately $7,803,000.
Sionna Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Further Reading
Before you consider Sionna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sionna Therapeutics wasn't on the list.
While Sionna Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
